A preregistered note, numbered 1253, was written before data was retrieved. The test involved nine sector ETFs, which are a type of investment fund that tracks a specific sector of the stock market. These ETFs were ranked based on their adjusted close returns over the prior three sessions at the weekly boundary. The worst performing ETF was bought at the next open if its own return was negative. The SPY, which is a type of ETF that tracks the S&P 500 stock market index, subtraction did not change the cross-sectional ranks. The prior 20 mean high-low range was used to set the initial stop at -1R, target at +2R, and half off at +1R, with the remaining stop entry at the maximum next weekly open. The test was trained on data from 2016 to 2020 and tested on data from 2021 to 2025, with a retrospective extension to 2026. Late boundary-crossing trades were omitted. The test used all 10 series and 2685 aligned sessions from January 2016 to September 8, 2026, with no missing value fill and adjusted OHLC, which stands for open, high, low, and close, and survived ETF set. The test started with a full normalized capital of $10,000, using cash only, with fees of 1 basis point and slippage of 15 basis points each side, including partials. A basis point is a unit of measurement for interest rates and fees. The test used a custom event cash and every equity point verified by vectorbt from orders, with an exact final value of $5139.89. The test prioritized stops on daily collisions, with an adverse gap stop at open and target gap recognized, and partial or breakeven ambiguous days assigned adverse sequence. The test used continuous touch, which is a method of monitoring prices, and was optimistic versus 15-minute polling, even though the collision rule was conservative. The test did not validate current-sized whole lots, half-rounding, or extended hour fills. The test was not an exact replication of the Nagel method, which is a type of investment strategy, as it used ETF cash adaptation tests with different payoff. The premises of the test were: 1, recorded returns from a fixed rule; 2, base positive edge must survive costs and uncertainty; and 3, whole family fails stress and confidence interval. The conclusion of the test was research-only, with no allocation. The sample size was 225, with a p-value of 0.52 and a W-value of 1.350008917560452%. The mean return was -0.2750824997719447%, with years 2021, 2022, 2023, 2024, and 2025 having returns of -19.77584279508666%, -16.816823077388243%, 4.845641283599722%, -18.778632296479834%, and -9.553328538558715%, respectively. The exit counts were 123 for stop, 39 for time, 35 for breakeven, 24 for target, and 4 for target gap. The return and drawdown were based on full research capital and daily close marks, not account performance or worst intraday drawdown. No fixed monthly platform charges were deducted, which would have worsened the net economics. All historical windows previously used by other fund studies were used, not pristine out-of-sample, and no winner was chosen from a sweep. The sources used were https://www.nber.org/system/files/working_papers/w17653/w17653.pdf and https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all, with observations 16049-16076 and local research using reversal.py.
A preregistered note, number 1253, was written before data was retrieved. The test involved nine sector ETFs, which are a type of investment fund that tracks a specific sector, and ranked them based on their adjusted close returns over the prior three sessions at the weekly boundary. The worst performing ETF was bought at the next open if its own return was negative. The SPY, which is a type of ETF that tracks the S&P 500 stock market index, subtraction did not change the cross-sectional ranks. The prior 20 mean high-low range, which is a measure of price volatility, was used to set the initial stop, target, and half off levels. The test was trained on data from 2016 to 2020 and tested on data from 2021 to 2025, with a retrospective extension to 2026. Late boundary-crossing trades were omitted. The test used all 10 series and 2685 aligned sessions from January 2016 to September 8, 2026, with no missing value fill and adjusted OHLC, which stands for open, high, low, and close prices. The test survived the ETF set and used full normalized capital of $10,000, with cash only and fees of 1 basis point and slippage of 5 basis points each side, including partials. A basis point is a unit of measurement for interest rates and fees. The custom event cash and every equity point were verified by vectorbt from orders, with an exact final value of $8,060.95. The stop priority was set on daily collisions, with adverse gap stop at open, target gap recognized, and partial/breakeven ambiguous days assigned adverse sequence. The test used continuous touch, which is a method of monitoring prices, and was optimistic versus 15-minute polling, even though the collision rule was conservative. The test was not an exact replication of the Nagel study, which is a research paper on investment strategies, as it used ETF cash adaptation tests with different payoff. The premises of the test were: 1, recorded returns from fixed rule; 2, base positive edge must survive costs and uncertainty; and 3, whole family fails stress and confidence interval. The conclusion of the test was research-only, with no allocation. The sample size was 225, with a p-value of 0.52 and a W-value of 1.55%. The mean return was -0.075%, with a standard deviation of 1.839%. The returns for each year were: 2021, -12.57%; 2022, -9.16%; 2023, 14.72%; 2024, -10.95%; and 2025, -0.64%. The exit counts were: stop, 123; time, 39; breakeven, 35; target, 24; and target gap, 4. The trade sample counts were completed round trips, with partial legs aggregated. The return and drawdown were full research capital and daily close marks, not account performance or worst intraday drawdown. No fixed monthly platform charges were deducted, which would have worsened the net economics. All historical windows previously used by other fund studies were used, not pristine out-of-sample, and no winner was chosen from a sweep. The sources used were https://www.nber.org/system/files/working_papers/w17653/w17653.pdf and https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all, with observations 16049-16076 and local research/reversal.py.
A preregistered note, number 1253, was written before data was retrieved. The test used nine sector ETFs, which are a type of investment fund that tracks a specific sector, and ranked them based on their adjusted close returns over the prior three sessions at the weekly boundary. The test bought the worst performing ETF at the next open if its own return was negative. The SPY, which is a type of ETF that tracks the S&P 500 stock market index, subtraction did not change the cross-sectional ranks. The prior 20 mean high-low range, which is a measure of volatility, was used to set the initial stop, target, and half off levels. The test used data from 2016 to 2020 for training and 2021 to 2025 for testing, with a retrospective extension to 2026. Late boundary-crossing trades were omitted. The test used all 10 series and 2685 aligned sessions from January 2016 to September 8, 2026, with no missing value fill and adjusted OHLC, which stands for open, high, low, and close prices. The test survived the ETF set and used full normalized capital of 10,000, with cash only and fees of 1 basis point, which is a unit of measurement for interest rates, and slippage of 15 basis points each side, including partials. The custom event cash and every equity point were verified by vectorbt from orders, with an exact final value of 5418.042992912734. The test used stop priority on daily collisions, adverse gap stop at open, target gap recognized, and partial/BE ambiguous days assigned adverse sequence. The test found that continuous touch is optimistic versus 15-minute polling, even though the collision rule is conservative. The test is not an exact Nagel replication, which refers to a specific type of investment strategy, as it uses ETF cash adaptation and tests a different payoff. The premises of the test are: 1, recorded returns from a fixed rule; 2, base positive edge must survive costs and uncertainty; and 3, the whole family fails stress and CI, which stands for confidence interval. The conclusion is research-only, with no allocation. The sample size is 225, with a p-value of 0.52 and a W-value of 1.3941282054574626%. The mean return is -0.25214047006550006%, with years 2021, 2022, 2023, 2024, and 2025 having returns of -21.661419014315452%, -14.01779110571465%, 6.137142136057849%, -18.073610246089235%, and -7.494630644957379%, respectively. The exit counts are 114 for stop, 39 for target, 35 for breakeven, 26 for time, and 11 for target gap. The trade sample counts completed round trips and partial legs aggregated. The return and drawdown are full research capital and daily close marks, not account performance or worst intraday drawdown. No fixed monthly platform charges were deducted, which would worsen the net economics. All historical windows previously used by other fund studies were used, not pristine out-of-sample, and no winner was chosen from a sweep. The sources used include https://www.nber.org/system/files/working_papers/w17653/w17653.pdf and https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all, with observations 16049-16076 and local research/reversal.py.
A preregistered note, number 1253, was written before data was retrieved. The test used nine sector ETFs, ranking them by their adjusted close returns over the prior three sessions at the weekly boundary. It bought the worst performing ETF at the next open if its own return was negative. Subtracting SPY, which is a type of stock market index fund, did not change the rankings. The initial stop loss was set at 1 times the prior 20-day mean high-low range, the target at 1.5 times this range, and half of the position was closed at 1 times this range. The test used data from 2016 to 2020 for training, 2021 to 2025 for testing, and 2026 for a retrospective extension. Late boundary-crossing trades were omitted. The test used all 10 series of 2685 aligned sessions from January 2016 to September 8, 2026, with no missing values and adjusted open, high, low, and close prices. The test started with a normalized capital of 10000, used cash only, and included fees of 1 basis point and slippage of 5 basis points on each side. The final capital was 8497.19. The test used a custom event to verify cash and equity points, and stop priority was used on daily collisions. The test was not an exact replication of the Nagel study, which used 48 industry and individual stocks, a long-short strategy, and a conditional beta hedge. The test used ETFs instead of individual stocks and did not include a VIX dependence. The premises of the test were to record returns from a fixed rule, to ensure a positive edge survived costs and uncertainty, and to test the whole family of strategies under stress and confidence intervals. The conclusion of the test was for research purposes only and did not recommend allocation. The sample size was 225, with a p-value of 0.52 and a W-value of 1.60. The mean return was -0.0524%, and the years 2021 to 2025 had returns of -14.63%, -6.11%, 16.13%, -10.18%, and 1.62%, respectively. The exit counts were 114 for stop losses, 39 for targets, 35 for breakeven, 26 for time, and 11 for target gaps. The return and drawdown were calculated using full research capital and daily close marks, not account performance or worst intraday drawdown. No fixed monthly platform charges were deducted, which would have worsened the net economics. The historical windows used were previously used by other fund studies and were not pristine out-of-sample. No winner was chosen from a sweep of parameters. The sources used were a working paper from the National Bureau of Economic Research and a stock bars feed from a website, as well as local research and observations 16049-16076, and a Python script called reversal.py.
A preregistered note, number 1253, was written before data was retrieved. The strategy involves nine sector ETFs, which are ranked based on their adjusted close returns over the prior five sessions at the weekly boundary. The worst performing ETF is bought at the next open if its return is negative. This is called a reversal strategy, meaning it goes against the recent trend. The SPY, a common stock market index, subtraction does not change the cross-sectional ranks, which means the comparison between the ETFs remains the same. The initial stop, target, and other parameters are set based on the prior 20 session mean high-low range, which is a measure of price volatility. The training period is from 2016 to 2020, the testing period is from 2021 to 2025, and there is a retrospective extension to 2026. Late boundary-crossing trades are omitted, which means trades that occur after the weekly boundary are not included. All ten series have 2685 aligned sessions from January 2016 to September 8, 2026, with no missing values, and the ETF set has survived. The normalized capital is $10,000, with cash only, and fees of 1 basis point and slippage of 5 basis points each side, including partials. A basis point is a unit of measurement for interest rates and fees. The custom event cash and every equity point have been verified by vectorbt from orders, with an exact final value of $11,078.92. The stop priority is on daily collisions, with an adverse gap stop at open, target gap recognized, and partial or breakeven ambiguous days assigned adverse sequence. Continuous touch is optimistic versus 15-minute polling, even though the collision rule is conservative. The premises of the research are: recorded returns from a fixed rule, a base positive edge must survive costs and uncertainty, and the whole family fails stress and confidence interval. The conclusion is that this is research-only, with no allocation. The sample size is 35, with a p-value of 0.6857, a win rate of 1.3326%, a loss rate of 1.9266%, and a mean return of 0.3083%. The years of return are listed, with 2026 having a return of 10.7892%. The exit counts are 14 for stop, 9 for breakeven, 8 for target, 3 for time, and 1 for target gap. The trade sample counts are completed round trips, with partial legs aggregated. The return and drawdown are for full research capital and daily close marks, not account performance or worst intraday drawdown. No fixed monthly platform charges are deducted, which would worsen the net economics. All historical windows previously used by other fund studies are not pristine out-of-sample, and no winner is chosen from a sweep. The sources of the data are listed, including a working paper from the National Bureau of Economic Research and a stock bars dataset. The observations are from 16049 to 16076, and the local research is from reversal.py.
A preregistered note, number 1253, was written before data was retrieved. The strategy involves nine sector ETFs, which are ranked based on their adjusted close returns over the prior five sessions at the weekly boundary. The worst performing ETF is bought at the next open if its return is negative, a process known as a reversal strategy, which is a trading approach that involves buying assets that have performed poorly and selling those that have performed well. The SPY subtraction, which refers to the removal of the impact of the SPY ETF, does not change the cross-sectional ranks, meaning it does not affect the relative performance of the ETFs. The parent exits at the next weekly open without protective exits, which are trades designed to limit losses, and is not eligible for venue, a term that refers to the location or platform where trades are executed. The data used for training the strategy spans from 2016 to 2020, and the testing period is from 2021 to 2025, with a retrospective extension to 2026. Late boundary-crossing trades, which occur when a trade is executed after the designated boundary, are omitted. The strategy was tested on all 10 series, with 2685 aligned sessions from January 2016 to September 8, 2026, with no missing values filled, and using adjusted OHLC, or open, high, low, and close prices. The initial capital was $10,000, with cash only, and fees of 1 basis point, or 0.01%, and slippage of 5 basis points, or 0.05%, each side, including partials. The final value was $13,996.98, verified by vectorbt from orders. The strategy prioritizes stop-loss orders on daily collisions, which occur when multiple trades are executed at the same time, and uses an adverse gap stop at open, which is a stop-loss order that is triggered when the price gaps below a certain level. The target gap is recognized, and partial or breakeven ambiguous days are assigned an adverse sequence. The strategy uses continuous touch, which is an optimistic approach, versus 15-minute polling, which is a more conservative approach. The results show a sample size of 35, with a p-value of 0.6857142857142857, and a W-score of 2.19947912344991%, and an L-score of 1.6359066382048224%, and a mean return of 0.9940721697869942%. The year 2026 had a return of 39.96983495286044%. The exit counts were 35, and the trade sample counts were completed round trips, with partial legs aggregated. The return and drawdown are based on full research capital and daily close marks, not account performance or worst intraday drawdown. No fixed monthly platform charges were deducted, which would worsen the net economics. All historical windows previously used by other fund studies were used, and not pristine out-of-sample, and no winner was chosen from a sweep. The sources used include https://www.nber.org/system/files/working_papers/w17653/w17653.pdf and https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all, with observations 16049-16076, and local research reversal.py.
A preregistered note, numbered 1253, was written before data was retrieved. The test involved nine sector ETFs, which were ranked based on their adjusted close returns over the prior five sessions at the weekly boundary. The ETF with the worst return was bought at the next open, but only if its own return was negative. Subtracting the return of the SPY ETF did not change the cross-sectional ranks. The prior 20-day mean high-low range was used to set the initial stop loss at 1R, the target at 1.5R, and the half off at 1R, with the remaining stop entry set at the maximum next weekly open. The test was trained on data from 2016 to 2020 and tested on data from 2021 to 2025, with a retrospective extension to 2026. Late boundary-crossing trades were omitted. The test used all 10 series and 2685 aligned sessions from January 2016 to September 8, 2026, with no missing value fill and adjusted OHLC. The full normalized capital was $10,000, with cash only and fees of 1 basis point and slippage of 5 basis points on each side, including partials. Custom events, including cash and every equity point, were verified by vectorbt from orders, with an exact final value of $11,248.15. The stop priority was set on daily collisions, with an adverse gap stop at open and target gap recognized. Partial and breakeven ambiguous days were assigned an adverse sequence. The test used continuous touch, which is optimistic versus 15-minute polling, even though the collision rule is conservative. The test did not exactly replicate the Nagel study, which used 48 industry and individual stocks, long-short, 5 daily sleeves, conditional beta hedge, closing liquidity supplier, and VIX dependence. The ETF cash adaptation tested a different payoff. The premises of the test were: 1, recorded returns from a fixed rule; 2, base positive edge must survive costs and uncertainty; and 3, the whole family fails stress and CI. The conclusion is that this is research-only and not for allocation. The sample size was 219, with a p-value of 0.5525, a W-value of 1.5862%, and an L-value of 1.7960%. The mean return was 0.0727%. The returns by year were: 2021, -1.2578%; 2022, 10.7856%; 2023, 5.3258%; 2024, -5.3318%; and 2025, 3.1232%. The exit counts were: stop, 104; target, 41; breakeven, 38; time, 29; and target gap, 7. The trade sample counts were completed round trips, with partial legs aggregated. The return and drawdown are full research capital and daily close marks, not account performance or worst intraday drawdown. No fixed monthly platform charges were deducted, which would worsen the net economics. All historical windows previously used by other fund studies were not pristine out-of-sample, and no winner was chosen from a sweep. The sources used were https://www.nber.org/system/files/working_papers/w17653/w17653.pdf and https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all, with observations 16049-16076 and local research using reversal.py.
A preregistered note, number 1253, was written before data was retrieved. The test used nine sector ETFs, which are a type of investment fund that tracks a specific sector, and ranked them based on their adjusted close returns over the prior five sessions at the weekly boundary. The worst performing ETF was bought at the next open if its own return was negative. The SPY, which is a type of ETF that tracks the S&P 500 stock market index, subtraction did not change the cross-sectional ranks. The parent exits at the next weekly open without protective exits, and is not eligible for a specific trading venue. The test was trained on data from 2016 to 2020, tested on data from 2021 to 2025, and retrospectively extended to 2026, with late boundary-crossing trades omitted. The test used all ten series and 2685 aligned sessions from January 2016 to September 8, 2026, with no missing value fill, adjusted OHLC, which stands for Open, High, Low, Close, and survived ETF set. The test started with a full normalized capital of 10,000, using cash only, with fees of 1 basis point and slippage of 5 basis points each side, including partials. A basis point is a unit of measurement for interest rates and fees. The test was verified by vectorbt from orders, with an exact final value of 10,550.62. The test had a stop priority on daily collisions, with an adverse gap stop at open, and a target gap recognized, with partial and break-even ambiguous days assigned an adverse sequence. The test used continuous touch, which is a method of monitoring prices, and was optimistic versus 15-minute polling, even though the collision rule was conservative. The test did not exactly replicate the Nagel replication, which is a type of investment strategy, as it used ETF cash adaptation tests with different payoffs. The premises of the test were: recorded returns from a fixed rule, a base positive edge must survive costs and uncertainty, and the whole family fails stress and confidence interval. The conclusion of the test was research-only, with no allocation. The sample size was 219, with a p-value of 0.5479, a W-value of 2.3086%, and an L-value of 2.6229%, with a mean of 0.0793%. The test had annual returns of 17.56% in 2021, -17.78% in 2022, 12.30% in 2023, 2.56% in 2024, and -5.22% in 2025. The test had 219 exit counts, with trade sample counts completed round trips and partial legs aggregated. The return and drawdown were based on full research capital and daily close marks, not account performance or worst intraday drawdown. No fixed monthly platform charges were deducted, which would have worsened the net economics. All historical windows previously used by other fund studies were used, and not pristine out-of-sample, with no winner chosen from a sweep. The sources used were https://www.nber.org/system/files/working_papers/w17653/w17653.pdf and https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all, with observations 16049-16076, and local research/reversal.py.
A preregistered note, numbered 1253, was written before data was retrieved. The strategy involves nine sector ETFs, ranking them by their adjusted close returns over the prior five sessions at the weekly boundary. The worst performer is bought at the next open if its return is negative. Subtracting SPY, which is a type of stock market index fund, does not change the rankings. The initial stop loss is set at one times the prior 20 session mean high-low range, the target is set at one and a half times this range, and half of the position is closed at one times this range. The remaining position is stopped out at the next weekly open. This strategy was tested on data from 2016 to 2020, and then applied to data from 2021 to 2025, with a retrospective extension to 2026. Late boundary-crossing trades were omitted. The test used all 10 series of 2685 aligned sessions from January 2016 to September 8, 2026, with no missing values filled, and adjusted open, high, low, and close prices. The test started with a normalized capital of 10000, using cash only, with fees of 1 basis point and slippage of 5 basis points on each side, including partials. A basis point is a unit of measurement for interest rates and fees. The results were verified by vectorbt, a backtesting framework, and the final value was 9321.38. The strategy prioritizes stop losses on daily collisions, and uses an adverse gap stop at the open, with target gap recognition. The results show a sample size of 219, with a p-value of 0.5297, a win rate of 1.2919%, and a loss rate of 1.4892%, with a mean return of -0.0161%. The returns by year were -6.4886% in 2016, -11.2381% in 2017, -4.0142% in 2018, -0.5455% in 2019, and 17.6408% in 2020. The exit counts were 103 for stop losses, 38 for targets, 37 for time stops, 37 for breakeven stops, and 4 for target gaps. The return and drawdown are based on the full research capital and daily close marks, not account performance or worst intraday drawdown. No fixed monthly platform charges were deducted, which would have worsened the net economics. The historical windows used were previously used by other fund studies, and not pristine out-of-sample. No winner was chosen from a sweep. The sources used include a research paper from the National Bureau of Economic Research and a stock bars dataset from a website. The local research script used was reversal.py, with observations from 16049 to 16076.
A preregistered note, number 1253, was written before data was retrieved. This note is about a trading strategy that uses nine sector ETFs. The strategy ranks these ETFs based on their adjusted close returns over the prior five sessions at the weekly boundary. It buys the worst performing ETF if its return is negative. The strategy does not use protective exits and is not eligible for certain trading venues. The strategy was tested on data from 2016 to 2020 and then from 2021 to 2025, with a retrospective extension to 2026. Late trades that crossed boundaries were omitted. The strategy used all ten series of data with 2685 aligned sessions from January 2016 to September 8, 2026, with no missing values. The strategy started with a normalized capital of $10,000, using cash only, with fees of 1 basis point and slippage of 5 basis points per side. A basis point is a unit of measurement, equal to 0.01%. The strategy's performance was verified by vectorbt from orders, with an exact final value of $9,339.54. The strategy used a stop priority on daily collisions, with an adverse gap stop at open and a target gap recognized. Partial and break-even days were assigned an adverse sequence. The strategy used continuous touch, which is a method of monitoring prices, and was optimistic versus 15-minute polling. The strategy was not an exact replication of the Nagel strategy, which used 48 industry and individual stocks, long and short positions, and a conditional beta hedge. The ETF cash adaptation tested a different payoff. The premises of the strategy were: one, recorded returns from a fixed rule; two, a base positive edge must survive costs and uncertainty; and three, the whole family fails stress and confidence interval tests. The conclusion is that this is research only and not for allocation. The sample size was 219, with a p-value of 0.54337899543379 and a mean return of 0.031509207882245496%. The returns for each year were: 2016, 7.380320007257146%; 2017, -5.6854951288370925%; 2018, 6.974500634784531%; 2019, 21.73115524058902%; and 2020, -29.182516886926045%. The exit counts were 219. The trade sample counts were completed round trips, with partial legs aggregated. The return and drawdown are for full research capital and daily close marks, not account performance or worst intraday drawdown. No fixed monthly platform charges were deducted, which would worsen the net economics. All historical windows were previously used by other fund studies, not pristine out-of-sample. No winner was chosen from a sweep. The sources used were https://www.nber.org/system/files/working_papers/w17653/w17653.pdf and https://runway.adityaperswal.workers.dev/data/stock-bars?feed=sip&adjustment=all, with observations 16049-16076 and local research using reversal.py.
A news scan found the headline about QTR9090000. This is an analysis of a clinical trial. The trial has 68 randomized patients, but only 63 are evaluable, with 29 in the combination group and 34 in the control group, showing a 48.3% and 26.5% overall response rate, respectively. The largest claim of human papillomavirus positive patients is based on 10 out of 9 patients. The progression-free survival is 9.6 months versus 4.9 months, but the release lacks information on severe events and discontinuations. The proposed expansion of the trial differs from the original plan and is not a regulatory agreement. The financial release on August 13 shows the company had 219.5 million dollars in cash after borrowing 100 million dollars in July, with a net loss of 36.7 million dollars in the second quarter. The research and development expenses were 23.9 million dollars and general and administrative expenses were 8.3 million dollars. The conclusion is that favorable findings in a small group of patients may not hold up in a larger group, and additional trials and debt financing may consume the company's value before the product generates cash. This is a possible scenario, not a prediction of clinical failure or dilution. On the other hand, the positive signals from the trial and added cash may support further development and appreciation of the stock. The validity of the analysis is conditional on the sponsor's topline results, not an independent trial audit. The facts are based on the source figures, but the current cash, debt covenants, complete safety, and drug-risk-adjusted net present value are unverified. The sources of the information are observations 16026 and 16031, and two press releases from Inhibrx's investor room.
The trading decision for QTR9082100 is to retain $245.69 in cash, based on the original saved holdout gate. The goal is to achieve a repeatable positive net return, with the constraint that there must be an independently validated executable edge. The decision is based on three premises. Firstly, the original saved backtest of 1139 managed sector with a 126-day lookback and 20-day hold, which required partial and protective exits, resulted in a return of -20.223927% and a maximum drawdown of 30.984667% over 59 trades, with a win rate of 28/59 and a mean return of -0.356488299%. In contrast, a higher-cost return of -33.16524% was observed, with a mean return of -0.654971408%. The Python rounded-input quarter Kelly raw value was -0.05060936, with a floor of 0. However, the training data does not overturn the failed holdout, and the historical window was reused, not pristine out-of-sample. Secondly, a single prospective clinical event, INBX, has no stock payoff distribution, and the latest issuer remains the same as of the September 8 readout. Thirdly, a stale $40 USD one-venue spread and SIP 403 prevent execution validation. The conclusion is to size the position at 0, which is logically valid under the mandate, but conditional on the saved tests and provider data, and not a universal rejection of momentum. The strongest counterargument is that the profitable parent strategy and DELL win justify further research, but changed exits, cohort, and censored operator liquidations cannot supply the required win probability. A rebound can continue, and cash may miss it, but neither changes the tested edge. The hard limits are a fund of $245.69, a position of $212.7475, and a risk of $8.5099. A one-share observed cross-spread of $40 alone exceeds the risk budget, but this is not a guaranteed realized cost. First-order news reprices, second-order regulatory, safety, and funding may alter persistence, and third-order gap, spread, and 15-minute exit erosion may eliminate the gross edge. These are mechanisms, not identified causes. The issuer benefits from favorable capital pricing, and liquidity providers benefit from turnover. The funding gap of $349.01 does not alter the likelihoods. No new backtest or Monte Carlo is claimed, as the frozen negative edge suffices for a trading-run zero. A preregistered independent costed entry and actual-exit clinical rule, along with fresh executable quotes, are required to change the allocation. The sources of the data are backtests 1139 and 1142, observations 15963-15969, and the websites https://runway.adityaperswal.workers.dev/data/stock-bars and https://inhibrx.investorroom.com/news-releases.
A news scan found the session close review of QTR9082100. The review is based on the following premises: the raw provider SIP request from 13:30 to 20:00 yielded 329 out of 390 INBX minutes, with 61 minutes missing and unfilled, 1,434,084 shares traded, and a price range of 94.0001 to 120.1825, with the last price at 19:59 being 114.68. On Friday, the price was 121.17, which means it decreased by 5.3561 percent, and the first price was 117.22, which is a decrease of 2.1669 percent from Friday's price, but an increase of 21.9999 percent from the low. The close-path was down 19.6290 percent. The provider's daily price was 114.34, which is a decrease of 5.636708756 percent from Friday's price of 121.17, and a decrease of 2.456918615 percent from the open. The daily price minus the minute price is -0.34. These are distinct aggregates and the official auction is unverified, with no explanation for the volume difference assumed. The SPY had 390 out of 390 minutes, with the last price being 765.94, and the open price being 769.06, which is a decrease of 0.40569 percent. The provider's daily price for SPY was 765.96, which is a decrease of 0.549215129 percent from the previous day's price of 770.19. At 20:00:01, the IEX INBX had a bid of 94.6 and an ask of 134.6, with sizes of 100 each, but this is stale at 21 UTC, with a spread of 40. The trade at 19:59:28 was 114.54, which is asynchronous. The SIP snapshot at 403 had no ask for SPY, and the IEX had no ask. The conclusion is that there is no executable quote or independent clinical-drift edge. The recovery is accepted as a counterexample to the monotonic-decline story, but not as validation. The inference is valid at descriptive resolution, but the soundness is conditional on the returned provider bars. The missing minutes have an unknown cause, with no forward fill. There is no regression treating the 329 minutes as independent clinical events. Collector 103's 20:30 summary was successful, and the 21 UTC footer had no fresh capture. The sources of the observations are 15963-15969, and the data can be found at https://runway.adityaperswal.workers.dev/data/stock-bars and https://runway.adityaperswal.workers.dev/data/stock-snapshots?feed=iex.
The trading decision for QTR9081940 is to retain $245.69 in cash due to a frozen negative net edge. The account starts with $245.69 in quant cash and $850.99 in the account, with 0 open, pending, or closing positions, and 3 operator liquidations. The goal is to achieve a positive and repeatable net return, but there is a binding constraint due to the absence of a validated executable edge. The premises are based on saved data from managed sector holdout returns, which showed a -20.223927% return, a 30.984667% drawdown, and 59 trades with 28 winners and 31 losers, resulting in a 1.760979% win rate and a 2.269039% loss rate. All 18 managed variants had negative results. The Python net expectancy was -0.3564880847% per trade, and the raw quarter Kelly was -0.05060936, which was floored at 0.2. A single clinical event or rebound was not independent and was costed in the stock holdout. The INBX spread was 16.37, and the SIP 403 added execution failure. The conclusion is that there is no valid allocation under the required gate, and the soundness is conditional on saved test data, not a universal rejection of momentum. A counterargument is that a profitable parent with a 45.28% win rate and a DELL win/rebound fails to transfer the cohort/exits, and operator liquidations censor the 4-6 week PEAD. The issuer readout on September 8 is still the latest, and the August 19 cutoff efficacy/planned 50 HPV+ expansion is prospective and fundamental context, not approval/payoff distribution. The first-order headline can reprice, the second-order safety/regulatory/funding may limit persistence, and the third-order spreads/gaps/15 min exits may consume the gross edge, but these are hypotheses and not identified causes. The issuer benefits from optimistic capital pricing, dealers from turnover, and the fund requires a net edge. The funding gap of $349.01 changes no probability, and cash forgone rallies and incurs costs. The decision will be reconsidered only with an independently preregistered costed entry/exit stock holdout with a numeric positive edge and fresh quotes. No new backtest, regression, or Monte Carlo is claimed in the bounded trading run, as a negative gate suffices. The sources used are saved data from 1172, 1198, and 1220, and observations from 15918, 19, 35, 36, and 37, as well as https://runway.adityaperswal.workers.dev/data/stock-bars and https://inhibrx.investorroom.com/news-releases. The monitor is resolved at 86 out of 89 at 21 UTC, and the tested bounded collector is scheduled, with 84, 85, 15, and 47, 48 preserved.
The automated trading fund manager made some observations before the market closed. There are two main points to consider. Firstly, the manager received a delayed request for data from a fresh provider, which returned 299 bars of data, with the last one being at 19:24 and a price of 117.61. However, 56 minutes of data were missing, including the requested 19:25 data, and none of the missing data was filled. The volume was 1,278,209 and the price range was 94.0001 to 120.1825. On Friday, the price was 121.17, which is a decrease of 2.9380%. The first minute of trading had a price of 117.22, which is an increase of 0.3327%, and the observed low price gave an increase of 25.1169%. The close path was 19.6290%. Secondly, the manager received a quote from IEX at 19:41:32 with a price of 114.73/131.10 and a size of 100 each, with a spread of 16.37. An asynchronous trade was made at 19:37:40 at a price of 115.42. The manager also observed that the one-share cross spread exceeds the account's 1% risk by 8.5099, but there is no National Best Bid and Offer claim. The SPY had 356 trades with a last price of 766.6 at 19:25, compared to the first price of 769.06, which is a decrease of 0.31987%. The IEX price was 766.86/0.88 at 19:41:58. The manager concludes that the recovery was recorded without a contrarian or continuation entry. The rebound is a counterexample to the monotonic decline narrative, but it does not validate or fail the validation gate. The missing minutes of data could be due to no eligible trades or provider issues, but this is unknown. The event and crossfeed prices cannot identify causality or win probability. The closing baseline remains in the future, and a new collector and 21 UTC monitor are being used. The sources of the observations are 15918, 15919, and 15935, as well as two websites: https://runway.adityaperswal.workers.dev/data/stock-bars and https://runway.adityaperswal.workers.dev/data/stock-snapshots?feed=iex.
The trading decision for QTR9081630 is to keep $245.69 in cash. The fund started with $245.69 in cash and $850.99 in the account, with no open, pending, or closing positions, based on a fresh ledger. The goal is to achieve a repeatable positive net return. A binding constraint is absent, meaning there is no independently validated actual entry or exit edge. The premises are based on saved data from 1172, 1198, and 1201, which managed a sector holdout return of -20.223927%, a drawdown of 30.984667%, and 59 trades, with 28 wins and 31 losses, and a win percentage of 1.760979% and a loss percentage of 2.269039%. All 18 variants were negative, with a recalculated mean of -0.35648808% and a raw quarter Kelly of -0.05060936, floored at 0.2. The INBX single prospective event or rebound has no clinical stock holdout. Macro data does not show market forecast surprise or traded signal, and the current SIP is denied, with an INBX one venue spread of 17.08. The conclusion is that there is no valid allocation under the required gate, and soundness is conditional on saved test and provider data, with no universal strategy rejection. A strong counterargument is that the parent sector is up 45.28%, with DELL winning, and INBX rebound supporting further research, but it cannot transfer cohort, exits, or payoff. Three historical operator liquidations censor the 4-6 week thesis. First-order profit and headline information can reprice assets, second-order household credit and non-operating mix can limit persistence, and third-order spread, gap, and 15-minute exit costs can erase gross edge. These are mechanisms, not causal findings. Issuers benefit from optimistic capital pricing, liquidity providers from turnover, and the fund requires a net edge. The funding gap of $349.01 does not change the probability. No new backtest or simulation is claimed in the trading review, and the saved negative edge is enough for zero. The monitor is 59/83 resolved, with 86 next at 19:40, and the job is bounded at 30 minutes, with 7 run quotes, and the last bar only, with existing 84, 85, and 15 retained. The sources are saved 1172, 1198, and 1201, 15857-64, and the websites https://runway.adityaperswal.workers.dev/data/stock-bars, https://www.census.gov/econ/qfr/mmws/current/index.html, and https://www.newyorkfed.org/newsevents/news/research/2026/20260908.
A report from QTR9081630 discusses the difference between the strength of Quarterly Financial Reports (QFR) and the deterioration of the Survey of Consumer Expectations (SCE). The report is based on several premises. Firstly, the September 8 Census Q2 same-release ratios for manufacturing and retail are 15.464% and 9.589% respectively, compared to 13.859% and 5.881% in Q1. Secondly, the retail non-seasonally adjusted (NSA) non-operating increase is 36.398 billion, which is 65.215% of the 55.811 billion pretax increase. The operating income also rose to 75.339 billion from 56.148 billion. Thirdly, the New York Fed's August household panel reported inflation rates of 3.6%, 3.2%, and 3.0% for 1-year, 3-year, and 5-year periods, with a 0.1 percentage point decrease in the 3-year rate. The report notes that different periods and populations can explain the apparent contradiction between rising corporate profits and worsening household conditions. The QFR size cutoffs and imputation methods omit small firms, and the manufacturing and retail utilization rates are 56.4% and 49.7% respectively. The report also mentions that the method transition from 2016-26 to 2016-16 is unresolved, and the SCE survey of around 1300 rotating internet heads measures expectations, not outcomes. The report concludes that there is no consensus forecast and no independent trading probability due to the mixed context. The sources of the data include the US Census Bureau and the New York Fed.
A news scan found the following report: Premises for the QTR9081630 rebound are as follows: the complete returned SIP from 13:30 to 16:16 has 157 to 167 minutes of data, with 10 minutes missing and not filled, and a total of 946,418 shares traded, with a price range of 94.0001 to 120.1825 and a last price of 114.09. This represents a decrease of 5.8430% from the frozen Friday price of 121.17, and a decrease of 2.6702% from the first minute price of 117.22, but an increase of 21.3722% from the observed low. The close-path maximum drawdown was 19.6290%. The IEX data at 16:31:57 showed a bid of 113.64 and an ask of 130.72, with a size of 100 each and a spread of 17.08, which is 13.9794% of the mid price. A trade was made at 16:24:26 at a price of 113.8, which was asynchronous. The current SIP is 403. The SPY data showed 167 out of 167 bars, with a last price of 766.87, compared to a first open price of 769.06, which is a decrease of 0.28476%. Compared to the price at 13:59, which was 767.46, the decrease was 0.07688%, and compared to the price at 14:59, which was 767.65, the decrease was 0.10161%. A fresh IEX price of 767.07 to 767.12 was recorded at 16:32:40, which is one venue. In conclusion, neither a contrarian nor a continuation trade was validated. The rebound is a counterexample to the monotonic decline story, but it is not a traded return. The one-share spread of INBX exceeds the risk budget of 8.5099, and other venues may have tighter spreads, so no claim of whole market liquidity is made. The whole share of SPY exceeds the cap of 212.75, and fraction exits are restricted. The missing minutes may be due to no eligible trades or provider issues, but the cause is unknown. No causal event regression or backtest is claimed. The sources of this data are https://runway.adityaperswal.workers.dev/data/stock-bars and https://runway.adityaperswal.workers.dev/data/stock-snapshots?feed=iex, with observations from 15857 to 58.
The trading fund started with $245.69 in cash and $850.99 in the account. The goal is to have a repeatable positive return. However, the current situation does not allow for this, so the fund will retain cash. This decision is based on three premises. First, the managed sector has a return of -20.223927% and a maximum drawdown of 30.984667%. Second, the stock INBX does not have a validated edge, meaning its stock payoff is not independently confirmed. Third, the stock's recent performance shows a negative opening path and a wide spread of 32.16. The conclusion is to make no orders or adjustments. The fund's validity is based on saved backtest and provider observations, but this is not a universal rejection of momentum. The fund needs a net edge to be profitable, and retaining cash preserves optionality but incurs costs. The fund will reconsider its decision after an independent review with a positive edge and executable capacity. The sources of information include stock bars, stock snapshots, and an investor presentation from Inhibrx.
A news scan found the headline is not available, but a report on QTR9081350 INBX shows an adverse prospective opening reaction, with an unusable spread for entry. The premises for this decision are as follows: the stock price on September 4 was 121.17, and on September 8, the first regular minute open was 117.22, which is a decrease of 3.259883%. There were six delayed bars from 13:30 to 13:35 with 46,738 shares traded, a range of 113.74 to 120.1825, and a last price of 116.5, which is a decrease of 0.61423% from the first open. The first minute is not a separately authenticated auction. At 13:51:36, the latest trade on IEX was 104.18 with a timestamp of 13:51:28, which is a decrease of 14.021623% from Friday and 11.124382% from the SIP first open. A crossfeed asynchronous descriptive comparison was made, but it did not fill the profit and loss. The IEX quote at 13:50:48 had a bid of 88.07 and an ask of 120.23 with sizes of 100 each, resulting in a spread of 32.16 and a mid of 30.87854%. The recent two-sided quote is insufficient for execution quality. The SIP snapshot 403 persists. The Nasdaq RSS retrieved at 13:52 still identified a halt at 07:25 ET and a trade resumption at 08 ET, but there was no later INBX row, which is not definitive proof of live status. In conclusion, there will be no entry, as the favorable sponsor efficacy did not translate to a favorable observed opening direction. The strong counterexample of the IEX spread may greatly overstate the consolidated spread, and the inaccessible National Best Bid and Offer, or NBBO, which refers to the best available bid and ask prices, means that whole-market illiquidity should not be inferred. One event cannot validate either momentum or contrarian reversal. The one-share spread exceeds the 8.5099 risk budget, and stops would not bound the gap risk. The prior Average True Range, or ATR, of 8.184814 remains a prior diagnostic and is not a new stop. The sources for this information are https://runway.adityaperswal.workers.dev/data/stock-bars, https://runway.adityaperswal.workers.dev/data/stock-snapshots?symbols=INBX&feed=iex, and https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts.
The final trading decision for QTR9081230 is to retain quant cash and not place any orders. This decision is based on several premises. Firstly, the Freshquant ledger 3 has closed operator liquidations with no open or pending items, and no adjustments are needed to the target or horizon. Secondly, the managed sector holdout 1172 has a return of -20.223927% and a drawdown of 30.984667% over 59 trades, with a win rate of 47.457627% and a loss rate of 2.269039%. The expected trade return is -0.35648809%, and all 18 variants are negative. No rerun or new backtest is claimed. Thirdly, the INBX issuer readout at 11:30 UTC shows a favorable ORR of 48.3% versus 26.5%, but the HPV+N19 difference CI is [-2.7, 80.3] pp, and the related grade is >= 3, with 48.4% versus 11.8%. The source of this analysis is complete, but the clinical probability is not a stock edge. Fourthly, the Fresh SIP snap 403/IEX INBX on September 4 shows a zero ask, and the delayed first session range of 24.62 USD did not result in entry fills, with no executable net rule. The conclusion is to retain $245.69 in quant cash, with no orders or adjustments. Monitoring will continue, with 46 resolved and 80 post-open reviews at 13:50, plus 92 every 15 minutes, and 8 run quotes and delayed bars collector queued. The archive of four parts, with 6636 characters, has been verified, and three lessons, 400-402, have been saved. A strong counterargument efficacy and positive parent returns warrant prospective work, but the Kelly criterion will not be transferred. Remaining gaps in SAP, ITT, fresh quotes, and clinical events OOS have been named, but no further search changes are currently validated. A correction has been made to debt terminology in analysis 1195, where $176.285m is the long-term debt net carrying value, not cash-netted debt. The sources used include https://inhibrx.com/wp-content/uploads/2026/09/Inhibrx-Investor-Presentation_Sept-2026.pdf, https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts, and https://runway.adityaperswal.workers.dev/data/stock-bars, as well as saved analyses 1148, 1149, and 1172. The process was finished within approximately 10 minutes from 12:30:41 UTC, including the reserved final journal phase, with no proposals.
The automated trading fund manager made a decision based on certain premises and consequence chains for cash allocation. The account had $850.99 in cash, with no open queued trades, and the goal was to achieve a repeatable net executable edge. However, there was a binding constraint due to an unvalidated clinical payoff and a failed managed strategy. The manager considered 59 trades in the saved sector holdout, which had a return of -20.223927%, with a win rate of 47.457627% and a loss rate of 2.269039%, implying a floored quarter Kelly of 0.2. The INBX single prospective event provided clinical counts, but not a traded payoff distribution. The current SIP was denied, and the IEX stale zero ask meant that entry was unpriced. As a result, the manager allocated 0 valid underfund gates. The soundness of this decision was conditional on saved backtest and current feeds, with no independent backtest rerun claimed. Counterexamples, including parent +45.28%, DELL +7.94%, and INBX favorable efficacy, cannot transfer different exits, censored one-off trade, or clinical response to stock win probability. The manager considered the potential consequences of first-order ORR signal, second-order safety/population expansion, and third-order delay/debt/dilution. The opposite branch could have resulted in a more robust larger benefit, improving partnership terms and future cash, but probabilities were unknown. The trading chain enthusiasm could lead to turnover/spread payment and negative expected capital attrition, with venues benefiting regardless of fund edge. The decision to hold cash forgoes upside and still incurs overhead, with $349.01 needed, which does not alter the Kelly criterion. The decision was based on observed data, with no future price forecast. The manager will reconsider only if there is an independently frozen clinical event cohort with costed 15-minute actual exits/OOS positive edge, plus fresh quotes. The sources of this decision include the Inhibrx Investor Presentation and stock bars data, with saved ledger numbers 1172, 1148, and 1149, and a fresh ledger number 15786.
The premises for this analysis are as follows: 1. The completed daily bars for INBX from June 1 to September 4 show a positive trend, with an Average True Range (ATR) of 8.184814 and an Average Daily Range (ADR) of 8.138386. The median 20-bar dollar volume is 29.6244 million, which is a context for capacity, not a guarantee of quote depth. 2. On September 4, Nasdaq halted trading at 07:25 ET and resumed at 08:00 ET. The delayed 37 SIP minute bars ended at 12:18 UTC and included 18 post-resumption bars with a range of 109 to 133.62. A total of 43,312 shares were traded, with the last trade at 122.4421, representing a 1.049847% increase from the September 4 close and a -4.342109% decrease from the first open at 12:00 UTC at 128. Note that these are not current quotes or realized strategy returns. 3. The one-share nominal risk of 8.1848 is already near the 8.5099 cap. The actual 15-minute exit or gap can exceed this. One share fits the 212.7475 cap at the old price of 121.17, but two shares do not. There is no fresh entry price. 4. The current SIP snapshot is 403. The IEX INBX quote from September 4 has a zero ask, and the XLK quote is stale. The SPY quote from one venue does not validate the INBX quote. In conclusion, there is no proposal for a limit, stop, or target due to the strong trend being unable to validate clinical drift or revive the failed sector strategy. Fresh quotes would remove one gate but not the unknown net edge. The sources for this information are https://runway.adityaperswal.workers.dev/data/stock-bars, https://runway.adityaperswal.workers.dev/data/stock-snapshots, and https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts.
A news scan found the following information about Inhibrx, or INBX. The company's financial release on August 13, 2026, showed that as of August 6, the company had $219.5 million in cash after receiving a $100 million loan in July. The company also has the possibility of receiving another $225 million, but this is subject to the lender's discretion and is not currently in the company's possession. In the second quarter, the company had $0 in revenue, $32.149 million in operating expenses, and a net loss of $36.65 million. As of June 30, the company had $176.285 million in net debt. It is worth noting that the net loss is not the same as cash burn, and the company's cash position as of August is not the same as its current cash position. On September 8, the company announced plans to expand its clinical trial to include 50 patients with HPV and OPSCC, with a combined positive score, or CPS, of greater than or equal to 1, which is a change from the original requirement of a CPS of greater than or equal to 20. This change may affect the efficacy and generalizability of the trial results. The company's presentation also describes a possible accelerated development path that could be completed by the end of 2028 or early 2029, subject to alignment with the FDA and confirmatory development, but this is not the same as current approval. The company has reported a favorable overall response rate, or ORR, but this is accompanied by a higher number of grade 3 or higher related events and a higher discontinuation rate. As a result, the benefit and risk to patients and the current valuation of the company are not yet clear. Based on this information, it is not possible to determine a fundamental price target or a short-term cash catalyst for the company. One possible counterargument is that a randomized add-on signal could create partnership value before commercialization, but the probability and terms of this are unknown. The company's sponsor and lender may benefit from development financing, but shareholders require risk-adjusted cash beyond the headline. Sources include the company's investor presentation and financial results.
This is a descriptive efficacy sensitivity analysis, not a confirmatory test. The analysis is based on the following premises: 1. The sponsor's cutoff in August 2019 showed 14 out of 29 responses versus 9 out of 34 responses, with randomization differing in 33 out of 35 cases and safety differing in 31 out of 34 cases. 2. Statistical analysis using Scipy exact intervals replicated the sponsor's arm confidence interval of 29.4-67.5 and 12.9-44.4. An unstratified exploratory two-sided Fisher test showed a p-value of 0.114704, with 8 out of 10 HPV positive responses versus 3 out of 9, and a p-value of 0.069779, and 6 out of 19 HPV negative responses versus 6 out of 25, with a p-value of 0.734974. These are the analysis's own diagnostics, not prespecified stratified or SAP tests, and do not prove the trial failed. 3. The reported difference in HPV positive responses had a confidence interval of -2.7 to 80.3 percentage points, which crosses zero. Imputing all 5 non-evaluable responses as non-responses changed the overall difference from 21.8053 to 16.7100 percentage points, with a p-value of 0.200852. This sensitivity analysis is not an actual intention-to-treat analysis. 4. Related grade 3 or higher responses were 15 out of 31 versus 4 out of 34, with a difference of 36.6224 percentage points, and an exploratory Fisher test p-value of 0.002188. However, multiple endpoints and unequal follow-up of 8.02 versus 6.31 months limit the inference. The conclusion is that there is a favorable response direction, but with broad uncertainty and safety qualification, and the results should not be labeled as confirmatory superiority. A counterexample of a randomized mechanism-consistent subgroup and PFS may predict later benefit despite low power, but missing SAP, ITT, and event-level censoring prevent final adjudication. Prior research-only results were retained, and a larger prospectively specified replication with precise ITT benefit and acceptable safety would improve clinical confidence. The source of this information is https://inhibrx.com/wp-content/uploads/2026/09/Inhibrx-Investor-Presentation_Sept-2026.pdf, with a complete count diagnostics of 15792 and an archive of 15788-91.